We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current CLDX market cap is 1.79B. The company's latest EPS is USD -2.1317 and P/E is -12.67.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.52M | 4.13M | 156k | 2.5M | 3.19M |
| Operating Income | -41.24M | -47.63M | -40.61M | -46.32M | -52.13M |
| Net Income | -38.26M | -43.31M | -32.81M | -35.84M | -42.12M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 4.87M | 11.64M | 6.06M | 9.22M | 6.88M |
| Operating Income | -53.23M | -63.35M | -71.24M | -115.23M | -154.54M |
| Net Income | -50.88M | -59.78M | -70.51M | -112.33M | -141.43M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 280.26M | 465.63M | 868.85M | 845.59M | 823.18M |
| Total Liabilities | 33.54M | 36.46M | 30.23M | 31.93M | 37.27M |
| Total Equity | 246.72M | 429.17M | 838.61M | 813.66M | 785.91M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 122.93M | 235.84M | 444.65M | 352.74M | 465.63M |
| Total Liabilities | 28.91M | 26.48M | 25.18M | 26.53M | 36.46M |
| Total Equity | 94.03M | 209.36M | 419.48M | 326.2M | 429.17M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -74.76M | -107.29M | -40.64M | -69.97M | -125.3M |
| Investing | 65.38M | -105.78M | -315.21M | -361.93M | -314.18M |
| Financing | 1.08M | 218.46M | 436.11M | 439.82M | 441.06M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -46.42M | -40.4M | -60.91M | -103.73M | -107.29M |
| Investing | 17.08M | -98.22M | -216.16M | 89.94M | -105.78M |
| Financing | 16.26M | 171.23M | 272.37M | 4.08M | 218.46M |
| Market Cap | 1.79B |
| Price to Earnings Ratio | -12.67 |
| Price to Sales Ratio | 260.46 |
| Price to Cash Ratio | 51.48 |
| Price to Book Ratio | 4.18 |
| Dividend Yield | - |
| Shares Outstanding | 66.34M |
| Average Volume (1 week) | 1.16M |
| Average Volume (1 Month) | 1.04M |
| 52 Week Change | -13.15% |
| 52 Week High | 53.18 |
| 52 Week Low | 22.9291 |
| Spread (Intraday) | 1.17 (4.3%) |
| Company Name | Celldex Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.celldex.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
